Praxis Precision Medicines (NASDAQ:PRAX) Now Covered by Analysts at B. Riley Financial

Praxis Precision Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • B. Riley Financial initiated coverage with a “buy” rating and a $713 price target, implying 129.33% upside from the previous close.
  • Analyst opinion is broadly positive: Praxis has a “Moderate Buy” consensus and an average price target of $659.25, though two analysts rate the stock “Sell.”
  • Praxis reported quarterly EPS of -$3.23, beating analysts’ estimate of -$3.54 by $0.31.
  • MarketBeat previews top five stocks to own in December.

Investment analysts at B. Riley Financial initiated coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) in a research note issued to investors on Friday, Briefing.com reports. The brokerage set a "buy" rating and a $713.00 price target on the stock. B. Riley Financial's target price would indicate a potential upside of 129.33% from the company's previous close.

PRAX has been the topic of several other research reports. Wedbush lifted their price objective on shares of Praxis Precision Medicines from $188.00 to $189.00 and gave the stock an "underperform" rating in a research report on Tuesday, November 10th. Robert W. Baird increased their price objective on Praxis Precision Medicines from $514.00 to $568.00 and gave the company an "outperform" rating in a research note on Monday. JPMorgan Chase & Co. began coverage on Praxis Precision Medicines in a research report on Friday, October 16th. They set an "overweight" rating and a $700.00 price objective on the stock. Wells Fargo & Company set a $509.00 price objective on Praxis Precision Medicines and gave the company an "overweight" rating in a research note on Tuesday. Finally, Guggenheim boosted their price target on Praxis Precision Medicines from $800.00 to $1,050.00 and gave the stock a "buy" rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $659.25.

Check Out Our Latest Stock Analysis on PRAX

Praxis Precision Medicines Stock Performance

Shares of NASDAQ:PRAX opened at $310.90 on Friday. Praxis Precision Medicines has a 52 week low of $160.11 and a 52 week high of $392.70. The firm's fifty day moving average is $286.77 and its 200-day moving average is $314.30. The firm has a market cap of $8.69 billion, a PE ratio of -24.29 and a beta of 2.85.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($3.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.54) by $0.31. Sell-side analysts forecast that Praxis Precision Medicines will post -13.72 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new position in shares of Praxis Precision Medicines in the 2nd quarter worth about $2,524,000. Readystate Asset Management LP bought a new position in Praxis Precision Medicines during the second quarter valued at about $3,531,000. Swiss National Bank increased its position in shares of Praxis Precision Medicines by 15.3% during the 1st quarter. Swiss National Bank now owns 46,700 shares of the company's stock worth $15,046,000 after purchasing an additional 6,200 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Praxis Precision Medicines in the 2nd quarter valued at $2,698,000. Finally, Orbimed Advisors LLC grew its position in shares of Praxis Precision Medicines by 82.5% during the 1st quarter. Orbimed Advisors LLC now owns 172,500 shares of the company's stock worth $55,578,000 after buying an additional 78,000 shares during the period. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Praxis Precision Medicines Company Profile

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Recommended Stories

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Praxis Precision Medicines Right Now?

Before you consider Praxis Precision Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.

While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines